Bispecific Platforms: OmniFlic® and OmniClic®

About OmniFlic: A Common Light Chain Transgenic Rat

OmniFlic was designed based on the OmniRat experience and launched in 2014. It features:

  • The same heavy chain transgenes as OmniRat
  • A single rearranged VkJk light chain for the development of bispecific, fully human antibodies
  • Antibodies that comprise a single germline Vk sequence and can be generated through comprehensive analysis of the heavy chain repertoires

Like OmniClic, OmniFlic expresses the VK3-15 light chain so antibodies generated using these platforms can be combined to form a bispecific human antibody.

About the OmniClic transgenic chicken

The OmniClic transgenic chicken was specifically developed to facilitate the generation of bispecific antibodies. It was launched in 2019.

OmniClic was engineered to:

  • Focus sequence diversity on the CDRs of the VH domain
  • Express the VH3-23 and VK3-15 light chains, with a modified light chain transgene to minimize diversification
  • Generate diverse, high-quality affinity-matured antibodies

Like OmniFlic, OmniClic expresses the VK3-15 light chain so antibodies generated using these platforms can be combined to form a bispecific human antibody.

Scientific Publications

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics

Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies